S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
pixel
pixel
Log in
NASDAQ:UBX

Unity Biotechnology Stock Forecast, Price & News

$6.92
-0.21 (-2.95 %)
(As of 01/15/2021 12:00 AM ET)
Add
Compare
Today's Range
$6.81
Now: $6.92
$7.39
50-Day Range
$5.14
MA: $5.85
$7.13
52-Week Range
$2.72
Now: $6.92
$15.44
Volume1.18 million shs
Average Volume987,856 shs
Market Capitalization$366.16 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.15
Unity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to extend human health span. The company's lead drug candidates include UBX0101 that is in Phase II clinical trial for musculoskeletal/ osteoarthritis disease, as well as Phase Ib clinical trial for moderate-to-severe osteoarthritis of the knee; UBX1325, which is Phase I clinical trial for the treatment of diabetic macular edema; and UBX1967 for the treatment of ophthalmologic diseases. It is also developing programs in pulmonary disorders and neurological disorders, as well as kidney and liver diseases. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was founded in 2009 and is headquartered in South San Francisco, California.
Unity Biotechnology logo

MarketRank

Overall MarketRank

1.20 out of 5 stars

Medical Sector

720th out of 1,556 stocks

Biotechnology Industry

11th out of 80 stocks

Analyst Opinion: 1.1Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Biotechnology
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:UBX
CUSIPN/A
Phone650 416 1192
Employees76

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$366.16 million
Next Earnings Date3/10/2021 (Estimated)
OptionableNot Optionable
$6.92
-0.21 (-2.95 %)
(As of 01/15/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive UBX News and Ratings via Email

Sign-up to receive the latest news and ratings for UBX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Unity Biotechnology (NASDAQ:UBX) Frequently Asked Questions

How has Unity Biotechnology's stock price been impacted by COVID-19?

Unity Biotechnology's stock was trading at $5.39 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, UBX shares have increased by 28.4% and is now trading at $6.92.
View which stocks have been most impacted by COVID-19
.

Is Unity Biotechnology a buy right now?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Unity Biotechnology in the last year. There are currently 4 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" Unity Biotechnology stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in UBX, but not buy additional shares or sell existing shares.
View analyst ratings for Unity Biotechnology
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Unity Biotechnology?

Wall Street analysts have given Unity Biotechnology a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Unity Biotechnology wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Unity Biotechnology's next earnings date?

Unity Biotechnology is scheduled to release its next quarterly earnings announcement on Wednesday, March 10th 2021.
View our earnings forecast for Unity Biotechnology
.

How were Unity Biotechnology's earnings last quarter?

Unity Biotechnology, Inc. (NASDAQ:UBX) announced its quarterly earnings results on Wednesday, November, 4th. The company reported ($0.52) earnings per share for the quarter, missing analysts' consensus estimates of ($0.45) by $0.07.
View Unity Biotechnology's earnings history
.

What price target have analysts set for UBX?

5 brokerages have issued twelve-month price targets for Unity Biotechnology's shares. Their forecasts range from $4.00 to $5.00. On average, they anticipate Unity Biotechnology's stock price to reach $4.40 in the next twelve months. This suggests that the stock has a possible downside of 36.4%.
View analysts' price targets for Unity Biotechnology
or view Wall Street analyst' top-rated stocks.

Who are some of Unity Biotechnology's key competitors?

What other stocks do shareholders of Unity Biotechnology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Unity Biotechnology investors own include NIO (NIO), Inseego (INSG), NVIDIA (NVDA), Editas Medicine (EDIT), Advanced Micro Devices (AMD), (CGC), VBI Vaccines (VBIV), Enphase Energy (ENPH), Sorrento Therapeutics (SRNE) and OPKO Health (OPK).

Who are Unity Biotechnology's key executives?

Unity Biotechnology's management team includes the following people:
  • Dr. Nathaniel E. David, Co-Founder, Pres & Exec. Director (Age 52, Pay $640.86k)
  • Dr. Anirvan Ghosh, CEO & Director (Age 56)
  • Dr. Jan M. van Deursen, Founder
  • Dr. Judith Campisi, Founder
  • Mr. Daohong Zhou M.D., Founder
  • Ms. Lynne Marie Sullivan, Chief Financial Officer (Age 54)
  • Mr. Douglas A. Rich, Sr. VP of Operations (Age 51)
  • Mr. Alexander Azoy, VP of Fin., Chief Accounting Officer, Controller & Principal Accounting Officer (Age 44)
  • Dr. Daniel G. Marquess D.Phil, Chief Scientific Officer (Age 51)
  • Ms. Camille Landis, Sr. VP of Corp. Devel.

When did Unity Biotechnology IPO?

(UBX) raised $85 million in an initial public offering on Thursday, May 3rd 2018. The company issued 5,000,000 shares at a price of $16.00-$18.00 per share. Goldman Sachs, Morgan Stanley and Citigroup served as the underwriters for the IPO and Mizuho Securities was co-manager.

What is Unity Biotechnology's stock symbol?

Unity Biotechnology trades on the NASDAQ under the ticker symbol "UBX."

How do I buy shares of Unity Biotechnology?

Shares of UBX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Unity Biotechnology's stock price today?

One share of UBX stock can currently be purchased for approximately $6.92.

How big of a company is Unity Biotechnology?

Unity Biotechnology has a market capitalization of $366.16 million. Unity Biotechnology employs 76 workers across the globe.

What is Unity Biotechnology's official website?

The official website for Unity Biotechnology is www.unitybiotechnology.com.

How can I contact Unity Biotechnology?

The company can be reached via phone at 650 416 1192.

This page was last updated on 1/17/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.